Abstract
Objectives
Ximelagatran is a novel, oral direct thrombin inhibitor designed to overcome the low and variable oral absorption of melagatran, its active form. The pharmacokinetics and pharmacodynamics of ximelagatran following single and repeated oral administration were investigated. The primary objectives were to determine the dose linearity and reproducibility of melagatran exposure and the influence of food intake.
Methods
Two open-label studies were performed in healthy male subjects. Study I was a dose-escalation study, in which subjects received single oral doses of ximelagatran (1–98 mg). Study II was a randomised, two-way crossover study consisting of two 5-day treatment periods, in which subjects received a 20-mg oral dose of ximelagatran twice daily, either before breakfast and with dinner, or with breakfast and after dinner.
Results
Ximelagatran was rapidly absorbed and converted to melagatran, which was the predominant compound in plasma. The mean (± standard deviation) bioavailability of melagatran was 22.2±4.3% and 17.4±2.8% after single and repeated dosings, respectively. The maximum plasma concentration of melagatran and the area under the melagatran plasma concentration–time curve (AUC) increased linearly with dose. Inter- and intra-subject variability in melagatran AUC was 8% and 12%, respectively, with no relevant food- or time dependence. Anticoagulation, assessed as activated partial thromboplastin time, was correlated with melagatran plasma concentration. There was virtually no increase in capillary bleeding time over the dose range studied, and ximelagatran was well tolerated.
Conclusion
After oral administration of ximelagatran to healthy male subjects, the pharmacokinetic and pharmacodynamic profile of melagatran is predictable and reproducible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Williams GR, Jiang JG, Matchar DB, Samsa GP (1999) Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 30:2523–2528
Tarazzi L (1999) Clinical epidemiology of acute myocardial infarction. Am Heart J 138:S48–S54
Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593
Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:S64–S94
Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:S8–S21
Agnelli G, Mancini GB, Biagini D (2000) The rationale for long-term prophylaxis of venous thromboembolism. Orthopedics 23:S643–S646
Weitz JI, Hirsh J (2001) New anticoagulant drugs. Chest 119:S95–S107
Elg M, Gustafsson D, Deinum J (1997) The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 78:1286–1292
Elg M, Gustafsson D, Carlsson S (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94:187–197
Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sorensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110–118
Metha JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31:345–351
Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C (1997) Antithrombotic effect of two low-molecular-weight thrombin inhibitors and a low-molecular-weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 78:1404–1407
Mattsson C, Björkman JA, Ulvinge JC (1997) Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis. Fibrinol Proteolys 11:121–1218
Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hagg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Safwenberg U, Taghavi A, Thorsen M (1999) Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 81:358–363
Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, Sjöstedt Å, Folestad A, Arfwidsson A-C, Elvander CS, Frison L (2002). Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 105:371–378
Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 87:231–237
Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D (2002) Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360:1441–1447
Bredberg U, Eriksson U, Taure K, Frison L, Gustafsson D (1999) Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration. Blood 94:28a
Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171–181
Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A (2002) Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J. Chromatogr B 766:47–55
Acknowledgements
The authors acknowledge the valuable contribution of Dr. Paul Rolan and colleagues at Medeval in the planning and evaluation of these studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Eriksson, U.G., Bredberg, U., Gislén, K. et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 59, 35–43 (2003). https://doi.org/10.1007/s00228-003-0565-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0565-7